PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Health

New treatment may cure common hormonal cause of high blood pressure

A small study found that extended treatment with the aldosterone synthase inhibitor baxdrostat led to sustained blood pressure reduction for up to two years after patients stopped taking the drug.

7sources
8articles
5velocity
+89%since first seen
9d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

A study led by Queen Mary University of London and published in the New England Journal of Medicine found that a new treatment approach could offer a lasting cure for some people with primary aldosteronism, a hormonal cause of high blood pressure. The treatment, called extended aldosterone synthase inhibition (EASI), involves taking aldosterone synthase inhibitors such as baxdrostat for 6–12 months to target excess production of the hormone aldosterone. Unlike conventional treatments that control blood pressure, EASI appears to reverse the underlying cause, potentially removing the need for lifelong medication. Until now, a cure has required surgery to remove an entire adrenal gland.

The study followed 14 people treated at eight centers across the United States. Researchers found that EASI treatment led to sustained reversal of excess aldosterone production and partial or complete resolution of high blood pressure for up to two years after treatment ended. Hormone levels and blood pressure remained similar to, or lower than, those recorded during treatment. The main marker of excess aldosterone production remained 99% lower than before treatment, while blood pressure was, on average, 25 points lower. Almost a quarter of participants had normal blood pressure without taking any other medication.

Primary aldosteronism, in which benign nodules in the adrenal glands produce too much aldosterone, causes the kidneys to retain excess salt, raising blood pressure. It is estimated that between 5% and 10% of hypertension cases are caused by this condition. The scientific basis for EASI dates back to a 2005 experiment in mice showing that deleting the gene for aldosterone synthase caused aldosterone-producing cells to disappear. Researchers predicted prolonged inhibitor treatment might have a similar effect in humans.

Morris Brown, lead author and professor of endocrine hypertension at Queen Mary, said, "While duly cautious about our findings because of the pragmatic nature of the study, they were predicted by previous experiments, and longer follow-up may justify a claim that a finite course of medication leads to infinite cure. EASI treatment is unlikely to be the elixir for most patients with hypertension. But the possibility of tablets achieving a surgical cure has long been a holy grail for this common type of hypertension." Mason Freeman, professor of medicine at Harvard Medical School and initiator of the original study, said the follow-up generated "extraordinary and unexpected findings" offering "the very exciting possibility that many patients with primary aldosteronism may be able to be treated with a once-a-day pill, perhaps for a limited period of time, and obtain similar benefits to what we now achieve only after invasive diagnostic testing and major adrenal surgery."

In the United Kingdom, the drug is being assessed by the National Institute for Health and Care Excellence (NICE). Building on these findings, researchers are now leading a larger prospective clinical trial called ELIXIR to investigate whether EASI treatment can provide a lasting cure and will use molecular imaging to study whether prolonged treatment causes aldosterone-producing cells to disappear.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (95% supported) Updated 8d ago.

Quick answers

What is the new treatment for primary aldosteronism?

The treatment is called extended aldosterone synthase inhibition (EASI), which involves taking aldosterone synthase inhibitors such as baxdrostat for 6–12 months to target excess aldosterone production.

How long did the benefits last after patients stopped taking the drug?

The study found that sustained reversal of excess aldosterone production and partial or complete resolution of high blood pressure persisted for up to two years after treatment ended.

What percentage of hypertension cases are caused by primary aldosteronism?

It is estimated that between 5% and 10% of hypertension cases are caused by primary aldosteronism.

Coverage (8)

Topics

Related trends

\n \n \n \n \n \n \n